ROKIT Healthcare’s bioprinting-based diabetic foot treatment kit registered as a U.S. FDA medical device
Since 2019, the company has conducted clinical studies in India, Korea and Turkey, and based on the most recent study results in the U.S., the treatment has shown promising results in all of the study patients with no side effects.
The company reported that the study subjects were patients of chronic diabetic foot ulcer with an average of 64.4 years of age, 15 years of diabetes duration, and obesity in 90% of the patients.
The principal investigator behind the study is Dr. David G. Armstrong, PhD, DPM, who is Professor of Clinical Surgery at University of Southern California and has produced more than 510 peer-reviewed research papers in scholarly medical journals and 90 book chapters with expertise in the treatment and clinical care of the diabetic foot. Dr. Armstrong is past Chair of Scientific Sessions for the American Diabetes Association’s Foot Care Council and the founder and co-chair of the International Diabetic Foot Conference, the largest annual international symposium on the diabetic foot in the world.
“There is no existing method that resolves chronic diabetic foot ulcers by way of true regenerative medicine, especially for those ulcers that failed to close for many months,” said an official of ROKIT Healthcare. “We have seen our bioprinting-based diabetic foot ulcer treatment offer hope for patients who recovered and got back on their feet within just a few weeks after one procedure, making daily life possible again.
“The clinical study results have demonstrated that ROKIT Healthcare’s diabetic foot ulcer treatment kit can effectively regenerate skin of diabetic foot affected areas regardless of various variables such as race, age, and underlying disease. I can take one more step,” he said.
ROKIT Healthcare’s diabetic foot ulcer treatment, which consists of the printer Dr. INVIVO DFU and patient-specific autologous solution extraction kits, uses 3D scanning and AI-based interpretation of patient wounds to create customized skin regeneration patches.
“Given the FDA medical device registration and several successful global studies yielding promising results, we are proud to be leading a meaningful work of saving human lives with cutting-edge regenerative medicine technologies,” said Seok-Hwan You, CEO of ROKIT Healthcare. “I look forward to contributing to the advancement of chronic ulcer treatment methods and significantly improving the quality of life for patients.”
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
Reshaping Global Supply Chains: The UK’s First Advanced Manufacturing Plan
The day before the Biden administration announced around 30 broad-sweeping economic actions planned by the White House for 2024 and beyond — all surrounding the establishment of a new Council...
$1M to Drive Metal 3D Printing Adoption in ASTRO America Project with GE, Pratt & Whitney, and Honeywell
The Applied Science & Technology Research Organization of America (ASTRO America) has partnered with Pratt & Whitney, Honeywell, and GE on a project intended to ease adoption of metal additive...
AeroEdge and 3DOS Collaborate to Advance Additive Manufacturing in Japan
In a time when quick turnaround in manufacturing is essential, AeroEdge (TYO: 7409), a stalwart of the aerospace industry in Ashikaga, Japan, and 3DOS, a Silicon Valley-based tech company, have...
The Role of Private Equity in 3D Printing Service Consolidation
Amid looming concerns about a shaky economy, rising inflation, and climbing interest rates, private equity (PE) is stepping into the spotlight as a major player in the 3D printing world....
Upload your 3D Models and get them printed quickly and efficiently.